Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


HIV and malaria

INTRODUCTION

HIV and malaria infections often coexist in patients in many parts of the world due to geographic overlap of these two diseases. This is particularly true in sub-Saharan Africa, where an estimated 40 million people are living with HIV and more than 350 million episodes of malaria occur yearly [1]. There is also evidence of a negative interaction between these two infections. HIV increases the risk of malaria infection and the development of clinical malaria. Conversely, malaria increases HIV replication.

The significant interactions between HIV and malaria infections, including during pregnancy, will be reviewed here. Additional information regarding malaria in the HIV uninfected host is discussed separately. (See "Clinical manifestations of malaria" and "Treatment of uncomplicated falciparum malaria" and "Treatment of severe falciparum malaria".)

GENERAL PRINCIPLES

There are five malarial species that infect humans. Presently, most data on HIV interaction with malaria are derived from P. falciparum endemic regions of sub-Saharan Africa. However, as HIV spreads to areas endemic for P. vivax, similar important interactions may be identified.

Immunity to malaria — Immunity to malaria is characterized by an age-related reduction in parasite burden, clinical symptoms, and prevalence of severe disease in individuals residing in an endemic area [2]. P. falciparum infection and the burden of parasitemia are often less severe in older adults than in children. Children are at increased risk since they have not yet acquired natural immunity; pregnant women transiently lose some of their acquired immunity due to the relative immunosuppression of pregnancy. The degree of immunity is also related to transmission intensity, which varies geographically. HIV-related immunosuppression diminishes this acquired immunity. (See 'Impact of HIV on malaria' below.)

Clinical versus asymptomatic malaria — As discussed above, individuals living in endemic areas may develop partial immunity to disease following repeated infections. These "immune" individuals are not immune to infection per se. Following a bite by an infected mosquito, they will still develop parasitemia, but the severity of clinical symptoms is typically limited. This can affect estimates of clinical infection since patients who live in endemic areas are much less symptomatic and often have no symptoms. (See "Clinical manifestations of malaria".)

                            

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jun 2014. | This topic last updated: Feb 11, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Hewitt K, Steketee R, Mwapasa V, et al. Interactions between HIV and malaria in non-pregnant adults: evidence and implications. AIDS 2006; 20:1993.
  2. Karp CL, Auwaerter PG. Coinfection with HIV and tropical infectious diseases. I. Protozoal pathogens. Clin Infect Dis 2007; 45:1208.
  3. Froebel K, Howard W, Schafer JR, et al. Activation by malaria antigens renders mononuclear cells susceptible to HIV infection and re-activates replication of endogenous HIV in cells from HIV-infected adults. Parasite Immunol 2004; 26:213.
  4. Mermin J, Lule JR, Ekwaru JP. Association between malaria and CD4 cell count decline among persons with HIV. J Acquir Immune Defic Syndr 2006; 41:129.
  5. Mouala C, Houzé S, Guiguet M, et al. Imported malaria in HIV-infected patients enrolled in the ANRS CO4 FHDH study. J Acquir Immune Defic Syndr 2008; 49:55.
  6. Kublin JG, Patnaik P, Jere CS, et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet 2005; 365:233.
  7. Hoffman IF, Jere CS, Taylor TE, et al. The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. AIDS 1999; 13:487.
  8. Nunn AJ, Mulder DW, Kamali A, et al. Mortality associated with HIV-1 infection over five years in a rural Ugandan population: cohort study. BMJ 1997; 315:767.
  9. Crampin AC, Floyd S, Glynn JR, et al. Long-term follow-up of HIV-positive and HIV-negative individuals in rural Malawi. AIDS 2002; 16:1545.
  10. Morgan D, Mahe C, Mayanja B, et al. HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS 2002; 16:597.
  11. Jaffar S, Grant AD, Whitworth J, et al. The natural history of HIV-1 and HIV-2 infections in adults in Africa: a literature review. Bull World Health Organ 2004; 82:462.
  12. Patnaik P, Jere CS, Miller WC, et al. Effects of HIV-1 serostatus, HIV-1 RNA concentration, and CD4 cell count on the incidence of malaria infection in a cohort of adults in rural Malawi. J Infect Dis 2005; 192:984.
  13. Kamya MR, Gasasira AF, Yeka A, et al. Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J Infect Dis 2006; 193:9.
  14. Van Geertruyden JP, Mulenga M, Mwananyanda L, et al. HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria. J Infect Dis 2006; 194:917.
  15. French N, Nakiyingi J, Lugada E, et al. Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS 2001; 15:899.
  16. Laufer MK, van Oosterhout JJ, Thesing PC, et al. Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi. J Infect Dis 2006; 193:872.
  17. Whitworth J, Morgan D, Quigley M, et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000; 356:1051.
  18. Francesconi P, Fabiani M, Dente MG, et al. HIV, malaria parasites, and acute febrile episodes in Ugandan adults: a case-control study. AIDS 2001; 15:2445.
  19. Steketee RW, Wirima JJ, Bloland PB, et al. Impairment of a pregnant woman's acquired ability to limit Plasmodium falciparum by infection with human immunodeficiency virus type-1. Am J Trop Med Hyg 1996; 55:42.
  20. Müller O, Moser R. The clinical and parasitological presentation of Plasmodium falciparum malaria in Uganda is unaffected by HIV-1 infection. Trans R Soc Trop Med Hyg 1990; 84:336.
  21. Grimwade K, French N, Mbatha DD, et al. HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. AIDS 2004; 18:547.
  22. Butcher GA. T-cell depletion and immunity to malaria in HIV-infections. Parasitology 2005; 130:141.
  23. Cohen C, Karstaedt A, Frean J, et al. Increased prevalence of severe malaria in HIV-infected adults in South Africa. Clin Infect Dis 2005; 41:1631.
  24. Mouala C, Guiguet M, Houzé S, et al. Impact of HIV infection on severity of imported malaria is restricted to patients with CD4 cell counts < 350 cells/microl. AIDS 2009; 23:1997.
  25. Hendriksen IC, Ferro J, Montoya P, et al. Diagnosis, clinical presentation, and in-hospital mortality of severe malaria in HIV-coinfected children and adults in Mozambique. Clin Infect Dis 2012; 55:1144.
  26. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921.
  27. Abu-Raddad LJ, Patnaik P, Kublin JG. Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science 2006; 314:1603.
  28. Shah SN, Smith EE, Obonyo CO, et al. HIV immunosuppression and antimalarial efficacy: sulfadoxine-pyrimethamine for the treatment of uncomplicated malaria in HIV-infected adults in Siaya, Kenya. J Infect Dis 2006; 194:1519.
  29. Bloland PB, Wirima JJ, Steketee RW, et al. Maternal HIV infection and infant mortality in Malawi: evidence for increased mortality due to placental malaria infection. AIDS 1995; 9:721.
  30. Mount AM, Mwapasa V, Elliott SR, et al. Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection. Lancet 2004; 363:1860.
  31. Ticconi C, Mapfumo M, Dorrucci M, et al. Effect of maternal HIV and malaria infection on pregnancy and perinatal outcome in Zimbabwe. J Acquir Immune Defic Syndr 2003; 34:289.
  32. Ayisi JG, van Eijk AM, ter Kuile FO, et al. The effect of dual infection with HIV and malaria on pregnancy outcome in western Kenya. AIDS 2003; 17:585.
  33. ter Kuile FO, Parise ME, Verhoeff FH, et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-saharan Africa. Am J Trop Med Hyg 2004; 71:41.
  34. Schultz LJ, Steketee RW, Macheso A, et al. The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am J Trop Med Hyg 1994; 51:515.
  35. World Health Organization (WHO). A stategic framework for malaria prevention and control during pregnancy in the African region. Brazzaville: WHO Regional Office for Africa, 2004.
  36. Filler SJ, Kazembe P, Thigpen M, et al. Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi. J Infect Dis 2006; 194:286.
  37. Gill CJ, Macleod WB, Mwanakasale V, et al. Inferiority of single-dose sulfadoxine-pyrimethamine intermittent preventive therapy for malaria during pregnancy among HIV-positive Zambian women. J Infect Dis 2007; 196:1577.
  38. Ter Kuile FO, Steketee RW. Intermittent preventive therapy with sulfadoxine-pyrimethamine during pregnancy: seeking information on optimal dosing frequency. J Infect Dis 2007; 196:1574.
  39. Parise ME, Ayisi JG, Nahlen BL, et al. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. Am J Trop Med Hyg 1998; 59:813.
  40. Hamer DH, Mwanakasale V, Macleod WB, et al. Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women. J Infect Dis 2007; 196:1585.
  41. Green MD, van Eijk AM, van Ter Kuile FO, et al. Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya. J Infect Dis 2007; 196:1403.
  42. Bronzan RN, Taylor TE, Mwenechanya J, et al. Bacteremia in Malawian children with severe malaria: prevalence, etiology, HIV coinfection, and outcome. J Infect Dis 2007; 195:895.
  43. Kaplan JE, Benson C, Holmes KK, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.
  44. Sanders EJ, Wahome E, Mwangome M, et al. Most adults seek urgent healthcare when acquiring HIV-1 and are frequently treated for malaria in coastal Kenya. AIDS 2011; 25:1219.
  45. German P, Greenhouse B, Coates C, et al. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Infect Dis 2007; 44:889.
  46. Pham PA, Flexner C. Emerging antiretroviral drug interactions. J Antimicrob Chemother 2011; 66:235.
  47. Parikh S, Gut J, Istvan E, et al. Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 2005; 49:2983.
  48. Andrews KT, Fairlie DP, Madala PK, et al. Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria. Antimicrob Agents Chemother 2006; 50:639.
  49. Lek-Uthai U, Suwanarusk R, Ruengweerayut R, et al. Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum. Antimicrob Agents Chemother 2008; 52:2435.
  50. Hobbs CV, Voza T, Coppi A, et al. HIV protease inhibitors inhibit the development of preerythrocytic-stage plasmodium parasites. J Infect Dis 2009; 199:134.
  51. Achan J, Kakuru A, Ikilezi G, et al. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med 2012; 367:2110.
  52. Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364:1428.
  53. Mermin J, Ekwaru JP, Liechty CA, et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 2006; 367:1256.
  54. Kamya MR, Gasasira AF, Achan J, et al. Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS 2007; 21:2059.
  55. Walker AS, Ford D, Gilks CF, et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 2010; 375:1278.
  56. Campbell JD, Moore D, Degerman R, et al. HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea. Clin Infect Dis 2012; 54:1204.
  57. Thera MA, Sehdev PS, Coulibaly D, et al. Impact of trimethoprim-sulfamethoxazole prophylaxis on falciparum malaria infection and disease. J Infect Dis 2005; 192:1823.
  58. Miller JM, Korenromp EL, Nahlen BL, W Steketee R. Estimating the number of insecticide-treated nets required by African households to reach continent-wide malaria coverage targets. JAMA 2007; 297:2241.